Bernstein’s Tim Anderson is warning of a “patent cliff 2.0.”

Teva is launching AirDuo RespiClick and an authorized generic, the latter at a significant discount to GSK's Advair.

Tesaro has rolled out its ovarian cancer drug Zejula—and unveiled its so-far-secret list price, $9,833 per month. That looks like a discount to AZ's rival…

UniQure's trailblazing gene therapy has met its end. After struggling for years with the ultraexpensive Glybera, the company is calling it quits on the…

It was destined to happen: Amgen has sued Sanofi and Regeneron, claiming their newly approved Dupixent infringes one of its antibody patents.

The FDA posted a document outlining the issues that have undermined AstraZeneca's efforts to win approval for ZS-9.

The whistle continues to blow in a case alleging AstraZeneca defrauded Medicare by playing down the risks of its antipsychotic drug Seroquel, just not as…

As large drugmakers face growth challenges in the U.S. and other developed countries with burdened healthcare budgets, China is looking more and more enticing.

Pharma largely continued its price-hiking ways in 2016, and no wonder: The corresponding sales windfall equated to 100% of the industry’s overall earnings-per-…